Uncategorized

Serum Institute kickstarts production of Covovax vaccine at Pune facility ahead of clinical trials on children

The Serum Institute of India (SII) on Friday announced that the world’s biggest vaccine manufacturer has commenced the production of the first batch of the new Covid-19 vaccine ‘Covovax’, developed by Novavax, at their facility in Pune.

“A new milestone has been reached. This week we began our first batch of Covovax (a COVID-19 vaccine developed by Novavax) at our facility, here in Pune,” Serum Institute said in an official statement.

SII CEO Adar Poonawalla took to Twitter regarding the development and said that “the vaccine has great potential to protect our future generations below the age of 18”.

“Excited to witness the first batch of Covovax (developed by Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team,” he said.

 

The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies   

About the author

Avatar photo

The Dispatch Staff

Add Comment

Click here to post a comment